Piper Sandler raised the firm’s price target on AnaptysBio (ANAB) to $95 from $67 and keeps an Overweight rating on the shares. The firm notes AnaptysBio has traded up about 190% over the last year largely driven by the success of JEMPERLI’s launch and ANB033’s and eosinophilic esophagitis. Piper remains bullish on AnaptysBio and believes ANB033 represents a significant value proposition.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
- AnaptysBio Advances First Tracks Spin-Off and Governance Changes
- AnaptysBio announces $100M share repurchase program
- AnaptysBio board approves spin-off of First Tracks Biotherapeutics
- AnaptysBio price target raised to $90 from $70 at UBS